China’s Hopstem Biotech Secures Nearly RMB 200 Million in Series C First Close to Advance iPSC Cell Therapy Pipeline Led by hNPC01

August 17, 2026

Insight, China’s Pharmaceutical Industry China

Overview

China’s Hopstem Biotech has completed the first close of nearly RMB 200 million (approximately $27.5 million USD) in Series C funding to advance its iPSC cell therapy pipeline, led by hNPC01. hNPC01, human forebrain neural progenitor cells, has completed Phase 1 clinical trials and received both CDE and FDA IND approvals, as well as FDA Fast Track and RMAT designations for conditions like stroke and traumatic brain injury sequelae. The funding will support accelerated clinical development and preparation for commercial-scale production.

In Depth

Key Findings

Hopstem Biotech, a Chinese company specializing in iPSC (induced pluripotent stem cell) cell therapy, has successfully completed the first close of its Series C funding round, securing approximately RMB 200 million (around $27.5 million USD). This capital is specifically earmarked to accelerate the clinical development of its iPSC cell therapy pipeline, with a primary focus on its lead candidate, hNPC01. hNPC01, comprised of human forebrain neural progenitor cells, has already completed Phase 1 clinical trials and received Investigational New Drug (IND) approvals from both China’s CDE and the U.S. FDA, along with FDA Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for indications such as stroke and traumatic brain injury sequelae.

Technical / Clinical Details

hNPC01 consists of human forebrain neural progenitor cells derived from iPSCs. These cells are designed to repair brain tissue damaged by stroke and traumatic brain injury (TBI), aiming to restore lost neurological function. In preclinical studies, hNPC01 has shown promising results, including neural cell genesis, synapse formation, and functional improvements. Having completed Phase 1 clinical trials, its safety and tolerability profile has been established. The dual IND approvals from the CDE and FDA attest to the robustness of its development plan and regulatory confidence. The FDA’s Fast Track and RMAT designations, in particular, signify that hNPC01 is recognized as a potentially groundbreaking therapy for serious conditions, warranting expedited development and review.

Background & Context

Stroke and traumatic brain injury are leading causes of physical and cognitive disability worldwide, with existing treatments often unable to fully restore neurological function post-injury. These conditions involve significant neuronal loss and disruption of neural circuits. Regenerative medicine using iPSCs holds immense potential to replenish lost tissue and reconstruct functional neural connections. The proactive stance of global regulatory bodies, including those in China and the U.S., in facilitating the rapid market entry of such innovative cell therapies underscores the high expectation for breakthroughs in areas of significant unmet medical need.

Strategic Significance & Outlook

This Series C funding round will provide substantial momentum for the further clinical development of hNPC01, particularly its progression into Phase 2 and 3 trials. Additionally, preparations for establishing commercial-scale production will advance, marking a critical step towards future product commercialization. The FDA’s Fast Track and RMAT designations place Hopstem Biotech in a favorable position to strengthen regulatory collaborations and accelerate the approval process. Hopstem Biotech aims for hNPC01 to become one of the first cell therapies to significantly improve the quality of life for patients with stroke and TBI sequelae, with its upcoming clinical results and commercialization strategy eagerly anticipated. This development also highlights the increasing global competitiveness of Chinese companies in the field of iPSC-derived neural cell therapies.

Source: https://flcube.com/?p=72188

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.